Rob Sambursky, MD
President and Chief Executive Officer
Rob Sambursky has more than 25 years of industry and clinical medical experience. He is one of the original founders and Chief Executive of RPS Diagnostics, and currently leads Lumos Diagnostics as its President and Chief Executive Officer. He has served as the acting Chief Medical Officer for both RPS Diagnostics and for Lumos Diagnostics. In addition, Dr. Sambursky is a member of the Lumos Diagnostics Board of Directors, PPK Solutions Board of Directors, and serves as the Chairman for Visus Therapeutics, Inc. Dr. Sambursky has a strong scientific and clinical background in medical sciences, ophthalmology and infectious disease. He has authored numerous patents and scientific papers, conceived a novel point-of-care (POC) diagnostic test platform, served as the clinical and regulatory interface that led to multiple POC diagnostic tests obtaining international regulatory clearances as well as U.S. FDA 510(k) clearances with CLIA waiver designations, and successfully built a team that commercialized multiple diagnostic tests in the U.S. and abroad.
Dr. Sambursky is a board-certified ophthalmologist with fellowship training in refractive surgery and corneal external and infectious disease. He earned a BA in Biology from Brown University, an MA in Medical Sciences with concentrations in biochemistry and microbiology from Boston University and an MD from Boston University School of Medicine. Dr. Sambursky completed his internal medicine internship at Harvard’s Mount Auburn Hospital and both his ophthalmology residency and cornea fellowship at Wills Eye Hospital in Philadelphia.
Sacha Dopheide, PhD
Chief Technology Officer
Sacha Dopheide, PhD has more than 15 years of experience in the in vitro diagnostic device industry, ranging from point-of-care devices to laboratory analyzers. She currently serves as the company’s Chief Technology Officer and has held an executive leadership role within Lumos Diagnostics since its acquisition of Kestrel Bioscience in 2017. Dr. Dopheide has experience managing the full range of product development for both immunoassays and their accompanying electronic readers from proof of concept through development, verification and external validation trials. Dr. Dopheide has taken a leading role in identification and due diligence of M&A targets and integration activities. She also leads the Lumos Diagnostic service business unit’s business development activities, including directly conducting global market research, establishing partnerships and generating strategic product roadmaps for new tests.
Dr. Dopheide holds a BSc with First Class Honours in Biochemistry and Molecular Biology from Monash University. She received her PhD in Medicine in 2000, for which she was awarded the Victoria Fellowship for Excellence in Medical Research.
Jeffrey Bishop, PhD
Senior Vice President Research & Development
Jeffrey Bishop, PhD has more than 20 years of diagnostic industry experience. He currently serves as the company’s Senior Vice President of Research and Development. Prior to joining Lumos Diagnostics, Dr. Bishop was the Chief Scientific Officer, Senior Vice President of Diagnostic Operations and a member of the executive team at Singulex. Additionally, he held a variety of leadership positions within the research and development organization at Alere, Inc. (formerly Biosite, Inc.), including recent roles as Vice President, Research and Development for specific platforms and disease areas.
Dr. Bishop is a technical leader responsible for the successful development of more than 30 commercialized diagnostic assay products, including both instruments and assays for point-of-care, laboratory, life science and in vitro diagnostic applications. He has extensive experience with budgeting and strategic planning, clinical research and biomarker discovery, assay and system development, clinical, medical, and regulatory affairs, microfluidics, design control, and project management. Dr. Bishop has developed point-of-care assays in the areas of cardiovascular disease, infectious disease, women’s health and toxicology.
Dr. Bishop received both an MS and a PhD in Bioengineering from the University of California, San Diego and holds a BS in Chemical Engineering from Brigham Young University. He also holds an RAC certification in Regulatory Affairs.
Senior Vice President of Finance
Aaron Erlandson has more than 20 years of experience in financial leadership positions as well as a true passion for healthcare. He currently serves as the company’s Senior Vice President of Finance with responsibility for the company’s financial and accounting activities, including long-term business planning, forecasting, compliance, and audit functions. His diagnostics industry experience, with key roles in manufacturing, sales, corporate planning and analysis, has provided a deep understanding of the global value chain. Mr. Erlandson’s most recent accomplishments include global expansion projects across North America and Asia as well as developing and executing strategic investments valued over $600 million.
Mr. Erlandson earned dual undergraduate degrees in Corporate Finance and Psychology (Industrial/Organizational) from The University of Minnesota; as well as an MBA, with an emphasis in Corporate Entrepreneurship, from Babson College. He brings a unique perspective to financial and operational issues and leverages the role of finance as a change agent in organizations.
Senior Vice President of Corporate Strategy and Development
Jill Thompson has more than 25 years of experience in the life science and diagnostics industry. She currently serves as the company’s Senior Vice President of Corporate Strategy and Development.
Prior to joining Lumos Diagnostics, Ms. Thompson most recently served as President and Practice Leader for the JoLT Group where she provided management and consulting services to individuals and companies in all stages of business development. She is renowned for leading turnarounds, business development strategies, product development and commercialization projects, mergers and acquisitions, sales and distribution initiatives, licensing, joint ventures, market research, and implementing complex enterprise integrations.
She also served as Senior Vice President of Business Development at Orasure Technologies where she extricated the company from litigious situations, sourced rare reagents, and negotiated agreements that led to the rapid point-of-care Ebola test that was launched in Africa.
For more than 10 years, Ms. Thompson was Vice President of Business Development for Alere where she closed more than 15 deals ranging in value from $2M to over $100M. In this role, she transitioned accounts through multiple acquisitions, moved a $100M manufacturing business to China, and was pivotal in developing and launching three new diagnostic testing devices to expand the company’s product portfolio.
Ms. Thompson earned a BS in Psychology at Texas A&M University in College Station, TX.
Vice President of Operations
Kurt Phinney has 15 years of experience leading biomedical project management and manufacturing and serves as the company’s Senior Director of Operations. Mr. Phinney’s background includes development of biochemical assays (lateral flow, ELISA, western blot, and cell-based) with the State Laboratory Institute of Massachusetts, Immunetics and Floria Biosystems. His ongoing pursuit of novel biotechnology has resulted in multiple patents and FDA clearances. Mr. Phinney also provided consultation to biotechnology, information technology and pharmaceutical firms in the U.S. and overseas. Prior to this, he served as a Health Service Corpsman with the United States Coast Guard.
Mr. Phinney received a BS in Biology from the State University of New York at Albany.
Vice President of Product & Business Development
Jeff Bauer has been working in the diagnostics industry for over 35 years. He currently serves as the company’s Vice President of Product and Business Development. Mr. Bauer founded Kestrel BioSciences, a diagnostics R&D and manufacturing service business, with operations in Bangkok, Thailand and Carlsbad, California. In 2017, Kestrel BioSciences was acquired by Planet Innovation Pty Ltd and re-branded Lumos Diagnostics. Prior to the formation of Kestrel BioSciences, Mr. Bauer co-founded Diagnostic Consulting Network (DCN) where he was the Executive Vice President and Chief Scientific Officer.
Mr. Bauer has extensive product development and manufacturing experience in both human and animal health. He has expertise in developing immunoassays, such as ELISA, enzyme immunoassays, lateral flow, and point-of-care assays. He has ushered several products through FDA 510(k) clearance and international product registrations.
Mr. Bauer is a graduate of the U.S. Army Medical School in San Antonio, TX and is a Certified Medical Technologist with a specialty in Medical Microbiology.
Vice President of Information Technology
Jason Inman has more than 25 years of experience in the IT healthcare industry and currently serves as the company’s Vice President of Information Technology.
Mr. Inman has an extensive background in healthcare with IT leadership roles in a Fortune 500 healthcare plan, an organization with rehabilitation centers across the United States, and a start-up company specializing in behavioral health. Most recently he led a medical device manufacturer and distributor through its enterprise resource planning (ERP) and implementation and modernized the technology platform to support sales, manufacturing and accounting functions within the organization. He also has experience supporting regulatory and compliance organizational needs by proactively staying abreast of the changing landscape, creating and sponsoring projects, and providing support for ongoing reporting requirements.
Mr. Inman is a graduate of Brown University where he earned a BA in Organizational Behavior and Management.
Vice President of Corporate Marketing and Communications
Jennifer Christiansen has more than 20 years of strategic marketing and communications experience including 10 years with medical technology and clinical IT systems. She serves as the company’s Vice President of Corporate Marketing and Communications. Prior to joining Lumos, Ms. Christiansen held strategic planning, global marketing and corporate communications positions at Fortune 500 companies including GE Healthcare, Oshkosh Corporation and Labcorp. Her vast experience includes leading successful growth strategies, brand management, M&A and new product launch communications. Most recently she managed a strategic initiative to rebrand the Clinical Development division of Covance to Labcorp Drug Development. During her career, Ms. Christiansen has built global marketing organizations and fostered a continuous improvement culture by implementing new marketing processes and systems to optimize performance.
Ms. Christiansen is a graduate of the University of Wisconsin where she earned a BBA in Marketing. She is a certified Six Sigma Green Belt.
Senior Director of Human Resources
Sarah Glubka has more than 17 years of experience in human resources and currently serves as the company’s Senior Director of Human Resources.
Ms. Glubka most recently served as the Director of Human Resources for Australia-based Planet Innovation where she developed business initiatives, fostered employee engagement and mobilized talent. She was a key strategic business partner for the global product and service organization; working collaboratively with the leadership team and board of directors to establish strategies to ensure staff engagement. Ms. Glubka also championed, designed and implemented a successful company-wide employee health and safety program. Prior to Planet Innovation, Ms. Glubka was the Supervisor of Administrative Services for Kaiser Permanente where she developed payroll and attendance reports, metrics and analytics to support business needs and increase efficiencies. She also has expertise establishing human resource infrastructures for U.S. entities, including policies, standardized processes and procedures, and documentation to ensure compliance with all state and federal regulations as well as provide consistency in practice across the company.
Ms. Glubka earned a BS in Business Management from the University of Phoenix.
Senior Director of Medical Affairs
Annie Bell has more than 15 years of professional experience in the medical device and in vitro diagnostic industry including direct patient management, medical education and clinical study management. Currently serving as the Director of Medical Affairs for Lumos Diagnostics, Ms. Bell is a strategic leader with a passion for improving patient lives through early detection of disease. She has expertise in the initiation and oversight of clinical trials including FDA registration trials.
Ms. Bell holds a BS in Nursing from Pennsylvania State University, an MS in Nursing from Rush University Chicago, IL, and is a graduate of the Global Clinical Trials Clinical Research Program, Harvard Medical School, Boston MA. In addition, Ms. Bell is a Board-certified Neonatal Nurse Practitioner.
Senior Director of Regulatory Affairs
Sue Hibbeln has more than 15 years in Regulatory Affairs and Quality Assurance at start-up, mid- and large-sized companies for a variety of medical devices, including in vitro diagnostic devices, software, hardware, implants and sutures. She currently serves as the company’s Senior Director of Regulatory Affairs. Ms. Hibbeln specializes in global strategy, registration, regulatory/cultural intelligence and quality systems.
Her passion for working with diverse cultures has enabled opportunities to work with world-class talent on global cross-functional teams. Ms. Hibbeln especially enjoys helping clients with global remediation and harmonization efforts and monitors direction from the International Medical Device Regulators Forum (IMDRF). Ms. Hibbeln is a CMMI Associate and a certified appraisal team member (ATM) for the Medical Device Discovery Appraisal Program (MDDAP) – a joint initiative for FDA, MDIC, and CMMI.
Ms. Hibbeln earned a BA from LaSalle University, an MS in Regulatory Affairs from San Diego State University and a Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professionals Society (RAPS). She also completed the Kellogg Executive Leadership Program at Northwestern University.
Director of Quality Affairs
Huan Tran has 18 years of experience in both quality and regulatory affairs within the medical device and in vitro diagnostics industry. Mr. Tran currently serves as the company’s Director of Quality. He is a seasoned quality compliance leader with extensive experience in healthcare and medical device technology, data privacy, quality engineering and regulatory affairs, both in manufacturing and designing of immunoassays. Mr. Tran has specific expertise in FDA QSR, ISO 13485 certification, Canadian (CMDCAS) certification audits and HIPAA certification audits. Current responsibilities include overseeing all policies, procedures and products to ensure continued compliance with quality, regulatory and privacy requirements. Mr. Tran has proven success in achieving both U.S. and international regulatory clearances.
Mr. Tran earned a BS in Biochemistry from the University of California, San Diego and is a certified Lead Quality Management System Auditor (CLQA), Certified Quality Engineer (ASQ) and Certified HIPAA Professional (CHP).